Adverse effects of GLP – 1 Receptor Agonists
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nau...
Saved in:
Main Authors: | Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2025-02-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | https://apcz.umk.pl/JEHS/article/view/57774 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01) -
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01) -
Response to ‘Commentary on the published position statement regarding the pathogenesis of fetal basal ganglia- thalamic hypoxic-ischaemic injury’ (Anthony et al.)
by: I Bhorat, et al.
Published: (2023-12-01) -
GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01) -
Profile of STING agonist and inhibitor research: a bibliometric analysis
by: Xuemei Wang, et al.
Published: (2025-02-01)